Abstract
OBJECTIVE - Insulin degludec (IDeg) is a basal insulin that forms soluble multihexamers after subcutaneous injection, resulting in an ultra-long action profile. We assessed the efficacy and safety of IDeg formulations administered once daily in combination with mealtime insulin aspart in people with type 1 diabetes. RESEARCH DESIGN AND METHODS - In this 16-week, randomized, open-label trial, participants (mean: 45.8 years old, A1C 8.4%, fasting plasma glucose [FPG] 9.9 mmol/L, BMI 26.9 kg/m 2) received subcutaneous injections of IDeg(A) (600 μmol/L; n = 59), IDeg(B) (900 mmol/L; n = 60), or insulin glargine (IGlar; n = 59), all given once daily in the evening. Insulin aspart was administered at mealtimes. RESULTS - At 16 weeks, mean A1C was comparable for IDeg(A) (7.8±0.8%), IDeg(B) (8.0±1.0%), and IGlar (7.6 ± 0.8%), as was FPG (8.3 ± 4.0, 8.3 ± 2.8, and 8.9 ± 3.5 mmol/L, respectively). Estimated mean rates of confirmed hypoglycemia were 28% lower for IDeg(A) compared with IGlar (rate ratio [RR]: 0.72 [95% CI 0.52-1.00]) and 10% lower for IDeg(B) compared with IGlar (RR: 0.90 [0.65-1.24]); rates of nocturnal hypoglycemia were 58% lower for IDeg(A) (RR: 0.42 [0.25-0.69]) and 29% lower for IDeg(B) (RR: 0.71 [0.44-1.16]). Mean total daily insulin dose was similar to baseline. The frequency and pattern of adverse events was similar between insulin treatments. CONCLUSIONS - In this clinical exploratory phase 2 trial in people with type 1 diabetes, IDeg is safe andwell tolerated and provides comparable glycemic control to IGlar at similar doses, with reduced rates of hypoglycemia.
Original language | English (US) |
---|---|
Pages (from-to) | 661-665 |
Number of pages | 5 |
Journal | Diabetes care |
Volume | 34 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2011 |
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Advanced and Specialized Nursing